| 1.52 0.02 (1.33%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.22 | 1-year : | 2.69 |
| Resists | First : | 1.9 | Second : | 2.3 |
| Pivot price | 1.59  |
|||
| Supports | First : | 1.24 | Second : | 1.03 |
| MAs | MA(5) : | 1.46  |
MA(20) : | 1.68 |
| MA(100) : | 1.12 |
MA(250) : | 0.96 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.6 |
D(3) : | 21.1 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 2.3 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATOS ] has closed above bottom band by 38.6%. Bollinger Bands are 82.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 32 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.57 - 1.58 | 1.58 - 1.58 |
| Low: | 1.44 - 1.44 | 1.44 - 1.45 |
| Close: | 1.51 - 1.52 | 1.52 - 1.53 |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Wed, 24 Apr 2024
Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above 200 Day Moving Average of $1.00 - MarketBeat
Thu, 11 Apr 2024
Atossa therapeutics director buys $44,250 in company stock By Investing.com - Investing.com
Tue, 09 Apr 2024
Atossa Therapeutics reports positive data from breast cancer treatment trial - Proactive Investors USA
Wed, 03 Apr 2024
Atossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive Analysis - GuruFocus.com
Wed, 03 Apr 2024
Navigating Choppy Waters: Atossa Therapeutics' Struggle with Compliance Costs and Business Performance ... - TipRanks
Mon, 01 Apr 2024
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 125 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 19.1 (%) |
| Shares Short | 10,560 (K) |
| Shares Short P.Month | 7,150 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.9 % |
| Return on Equity (ttm) | -28.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -6.34 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|